Article Versions Notes

Cserepes M, Nelhűbel GA, Meilinger-Dobra M, Herczeg A, Türk D, Hegedűs Z, Svajda L, Rásó E, Ladányi A, Csikó KG, et al. EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. Cancers. 2022; 14(10):2407. https://doi.org/10.3390/cancers14102407

Cserepes, Mihály, Györgyi A. Nelhűbel, Mónika Meilinger-Dobra, Adrienn Herczeg, Dóra Türk, Zita Hegedűs, Laura Svajda, Erzsébet Rásó, Andrea Ladányi, Kristóf György Csikó, and et al. 2022. "EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer" Cancers 14, no. 10: 2407. https://doi.org/10.3390/cancers14102407

Cserepes, M., Nelhűbel, G. A., Meilinger-Dobra, M., Herczeg, A., Türk, D., Hegedűs, Z., Svajda, L., Rásó, E., Ladányi, A., Csikó, K. G., Kenessey, I., Szöőr, Á., Vereb, G., Remenár, É., & Tóvári, J. (2022). EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. Cancers, 14(10), 2407. https://doi.org/10.3390/cancers14102407